A Phase I/II B (randomized Controlled) Study of Atezolizumab Combined to BEGEV Regimen As First Salvage Treatment in Patients with Relapsed or Refractory Hodgkin's Lymphoma Candidate to Autologous Stem-cell Transplantation

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 06 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Bendamustine (Primary) ; Gemcitabine (Primary) ; Vinorelbine (Primary)
Indications Hodgkin's disease
Focus Adverse reactions; Therapeutic Use
Acronyms FIL_A-BEGEV

Most Recent Events

30 Jul 2024 Planned End Date changed from 8 Dec 2028 to 27 Apr 2030.
30 Jul 2024 Planned primary completion date changed from 8 May 2025 to 27 Apr 2027.
22 Dec 2022 Planned initiation date changed from 8 May 2022 to 1 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight